Skip to main content

Adagio Therapeutics, Inc. (ADGI)

NASDAQ: ADGI · IEX Real-Time Price · USD
38.73
6.20 (19.06%)
At close: Dec 7, 2021 4:00 PM
37.94
-0.79 (-2.04%)
After-hours:Dec 7, 2021 7:30 PM EST
Market Cap4.31B
Revenue (ttm)n/a
Net Income (ttm)-12.37M
Shares Out111.25M
EPS (ttm)-14.74
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,232,818
Open33.80
Previous Close32.53
Day's Range33.80 - 39.31
52-Week Range17.38 - 78.82
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ADGI

Adagio Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Our lead product candidate, ADG20, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent. We have completed enrollment in our first-in-human Phase 1 clinical trial of ADG20. We are also conducting two separate Phase 2/3 clinical trials: ...

IndustryBiotechnology
IPO DateAug 6, 2021
CEOTillman U. Gerngross
Employees68
Stock ExchangeNASDAQ
Ticker SymbolADGI
Full Company Profile

News

Will Adagio's COVID Antibody Therapy Be Too Late to the Party?

It's quite possible.

3 days ago - The Motley Fool

Adagio Therapeutics stock outlook as shares spike 35% on social media chatter

On Tuesday, Adagio Therapeutics Inc. (NASDAQ:ADGI) shares skyrocketed by more than 35% before declining for a mid-day net gain of about 4.5%. The rally was fueled by social media chatter, which saw trad...

1 week ago - Invezz

ADGI Stock: The Social Media Chatter That Has Adagio Therapeutics Soaring Today

Adagio Therapeutics (ADGI) stock is rising higher on Tuesday as investors on social media can't stop talking about the company. The post ADGI Stock: The Social Media Chatter That Has Adagio Therapeutics...

1 week ago - InvestorPlace

Adagio Therapeutics CEO: We see a role in the treatment of Covid, as well as prevention

Tillman Gerngross, Adagio Therapeutics CEO, joins 'The Exchange' to discuss how his company's antibody drug was developed and its effectiveness in fighting Covid variants.

1 week ago - CNBC Television

Morgan Stanley: Omicron will benefit this relatively new biotech firm

Adagio Therapeutics Inc (NASDAQ: ADGI) was up more than 75% on Monday after the biotech firm said Omicron was unlikely to be more resistant against its investigational monoclonal antibody, ADG20, despit...

1 week ago - Invezz

4 Top Biotech Stocks To Watch Now

With all eyes on the pandemic once again, these biotech players could be gaining more exposure.

Other symbols:NRXPVALNVIR
1 week ago - Stockmarketcom

ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential

Shares of ADGI stock are soaring higher by 80% after the company stated that its ADG-20 antibody is effective against the omicron variant. The post ADGI Stock Soars as Analysts Lock On to Its Omicron-Fi...

1 week ago - InvestorPlace

3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries

The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a handful of biopharma stocks, according to a Morgan Stanley an...

Other symbols:MRKPFE
1 week ago - Benzinga

Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Es...

Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing

1 week ago - GlobeNewsWire

Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Co...

WALTHAM, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of anti...

2 weeks ago - GlobeNewsWire

Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results

FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID-19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expec...

3 weeks ago - GlobeNewsWire

Adagio Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of anti...

3 weeks ago - GlobeNewsWire

Adagio Stock Jumps On Additional Preclinical Data For Its COVID-19 Antibody

Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new in vitro data demonstrating retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the new...

1 month ago - Benzinga

Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Kno...

Data to be presented at the 2021 ISIRV-WHO Virtual Conference Data to be presented at the 2021 ISIRV-WHO Virtual Conference

1 month ago - GlobeNewsWire

Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months

Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program.  Related Link:   Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial.

2 months ago - Benzinga

Adagio Therapeutics to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Day Conference

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of an...

2 months ago - GlobeNewsWire

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study

2 months ago - GlobeNewsWire

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021...

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021

2 months ago - GlobeNewsWire

Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial

Adagio Therapeutics Inc (NASDAQ: ADGI) announced that the independent data monitoring committee (IDMC) has recommended expanding the ADG20 EVADE Phase 2/3 trial for COVID-19. The IDMC has supported the ...

2 months ago - Benzinga

3 Biotech Stocks That Soared to New Heights Last Week

Find out what these industry favorites are doing to impress investors.

Other symbols:BCYCCERE
3 months ago - The Motley Fool

Adagio Therapeutics Announces Pricing of Initial Public Offering

WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics Announces Pricing of Initial Public Offering

4 months ago - Business Wire